The role of topotecan in prolongation of platinum-free interval in patients with recurrent ovarian cancer


Cite item

Full Text

Abstract

Nowadays disseminated ovarian cancer is a chronic disease, in the therapy of which one type of therapy completes the other; in case of recurrent ovarian cancer is important to change the regimens periodically. The choice of cytostatic drugs is quite wide, but in each case the tactic based on a combination of predictive factors, and also is important to take into account the toxicity after treatment. The article discusses the need and value of prolongation of platinum-free interval in relapsed ovarian cancer. In the preliminary assessment the Topotecan could be used as second-line and further-line treatment for recurrent ovarian cancer for platinum reinduction.

About the authors

E U Moskovskaya

ФГБУ Московский научно-исследовательский онкологический институт им. П.А.Герцена Минздрава России

Email: Moskovskayaeu@gmail.com
аспирант каф. онкологии ГБОУ ВПО Первый МГМУ им. И.М.Сеченова, отд-ния гинекологии отд. опухолей репродуктивных и мочевыводящих органов ФГБУ МНИОИ им. П.А.Герцена

E G Novikova

ФГБУ Московский научно-исследовательский онкологический институт им. П.А.Герцена Минздрава России

д-р мед. наук, проф., рук. отд-ния гинекологии отд. опухолей репродуктивных и мочевыводящих органов

I A Korneeva

ФГБУ Московский научно-исследовательский онкологический институт им. П.А.Герцена Минздрава России

Email: andavakor@gmail.com
канд. мед. наук, ст. науч. сотр. отд-ния гинекологии отд. опухолей репродуктивных и мочевыводящих органов

References

  1. Каприн А.Д., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2012 году. М.: ФГБУ МНИОИ им. П.А.Герцена Минздрава России, 2013.
  2. Ledermann J.A, Kristeleit R.S. Optimal treatment for relapsing ovarian cancer. Ann Oncol 2010; 21 (Suppl. 7): 218-22.
  3. Leitao M.M, Jr Kardos S, Barakat R.R, Chi D.S. Tertiary cytoreduction in patients with recurrent ovarian carcinoma. Gynecol Oncol 2004; 95 (1): 181-8.
  4. Fruscio R, Garbi A, Parma G et al. Randomized phase III clinical trial evaluating weekly cisplatin for advanced epithelial ovarian cancer. J Natl Cancer Inst 2011; 103 (4): 347-51.
  5. Hennessy B.T, Coleman R.L, Markman M. Ovarian cancer. Lancet 2009; 374 (9698): 1371-82.
  6. Vermorken J.B, Parmar M.K, Brady M.F et al. Clinical trials in ovarian carcinoma: study methodology. Ann Oncol 2005; 16 (Suppl. 8): 20-9.
  7. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E et al. Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum - sensitive ovarian cancer in late relapse. J Clin Oncol 2010; 28 (20): 3323-9.
  8. Markman M, Markman J, Webster K. Duration of response to second - line, platinum - based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J Clin Oncol 2004; 22 (15): 3120-5.
  9. Gordon A.N, Fleagle J.T, Guthrie D et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001; 19 (14): 3312-22.
  10. Herzog T.J, Sill M.W, Walker J.L et al. A phase II study of two topotecan regimens evaluated in recurrent platinum - sensitive ovarian, fallopian tube or primary peritoneal cancer: a Gynecologic Oncology Group Study (GOG 146Q). Gynecol Oncol 2011; 120 (3): 454-8.
  11. Hertzberg R.P, Caranfa M.J, Hecht S.M. On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme - DNA complex. Biochemistry 1989; 28 (11): 4629-38.
  12. Houghton P.J, Cheshire P.J, Hallman J.D 2-nd et al. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 1995; 36 (5): 393-403.
  13. Subramanian D, Kraut E, Staubus A et al. Analysis of topoisomerase I/DNA complexes in patients administered topotecan. Cancer Res 1995; 55 (10): 2097-103.
  14. Clements M.K, Jones C.B, Cumming M, Daoud S.S. Antiangiogenic potential of camptothecin and topotecan. Cancer Chemother Pharmacol 1999; 44 (5): 411-6.
  15. Van Warmerdam L.J.C, Verweij J, Schellens H.M et al. Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks. Cancer Chemother Pharmacol 1995; 35 (3): 237-45.
  16. Bolis G, Scarfone G, Raspagliesi F et al. Paclitaxel/carboplatin versus topotecan/paclitaxel/carboplatin in patients with FIGO suboptimally resected stage III-IV epithelial ovarian cancer a multicenter, randomized study. Eur J Cancer 2010; 46 (16): 2905-12.
  17. Bence A, Mattingly C. Evaluation of topotecan cytotoxicity and topoisomerase I levels in non - small cell lung cancer cells. Proc Am Assoc Cancer Res 2002; 43: 247. abstr 1227.
  18. Safra T, Menczer J, Bernstein R, Shpigel S. Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer. Gynecol Oncol 2007; 10: 10-6.
  19. Di Saia P.J, Creasman W.T. Clinical Gynecologic Oncology. 8th ed. Mosby 2012; р. 720.

Copyright (c) 2014 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies